Estrella Immunopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ESLA Nasdaq 2836 www.estrellabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Estrella Immunopharma, Inc.

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference - May 5th, 2026 6:00 am
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research - Mar 23rd, 2026 6:00 am
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T - Mar 18th, 2026 3:20 am
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL - Feb 9th, 2026 7:02 am
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Feb 9th, 2026 5:00 am
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Feb 3rd, 2026 6:00 am
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - Jan 6th, 2026 12:02 pm
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - Jan 5th, 2026 6:30 am
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Dec 4th, 2025 6:00 am
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either? - Nov 4th, 2025 10:13 am
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients - Nov 3rd, 2025 6:00 am
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Oct 6th, 2025 6:00 am
Is Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Deliver On Growth Plans? - Aug 14th, 2025 4:36 am
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Jun 5th, 2025 6:00 am
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Jun 3rd, 2025 6:00 am